Cohort1: CVnCoV Vaccine
|
Administration route |
intramuscular injection |
Dosage |
CVnCoV, 12 μg |
Pts |
19787 |
Age |
Adult, Older_Adult |
Adverse reactions |
17/19787(All-cause mortality); 149/19787(Blood and lymphatic system disorders; Cardiac disorders; Ear and labyrinth disorders; Endocrine disorders; Eye disorders; Gastrointestinal disorders; General disorders; Hepatobiliary disorders; Immune system disorders; Infections and infestations; Injury, poisoning and procedural complications; Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Pregnancy, puerperium and perinatal conditions; Psychiatric disorders; Renal and urinary disorders; Reproductive system and breast disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders) |
References |
PMID:
34826381
|
|
Cohort2: Placebo
|
Administration route |
intramuscular injection |
Dosage |
Placebo, 12 μg |
Pts |
19753 |
Age |
Adult, Older_Adult |
Adverse reactions |
14/19753(All-cause mortality); 111/19753(Blood and lymphatic system disorders; Cardiac disorders; Ear and labyrinth disorders; Endocrine disorders; Gastrointestinal disorders; General disorders; Hepatobiliary disorders; Immune system disorders; Infections and infestations; Injury, poisoning and procedural complications; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Pregnancy, puerperium and perinatal conditions; Psychiatric disorders; Renal and urinary disorders; Reproductive system and breast disorders; Respiratory, thoracic and mediastinal disorders; Skin and subcutaneous tissue disorders; Vascular disorders) |
References |
PMID:
34826381
|
|